Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.48
FGEN's Cash-to-Debt is ranked lower than
99.99% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. FGEN: 2.48 )
Ranked among companies with meaningful Cash-to-Debt only.
FGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.27  Med: 2.18 Max: N/A
Current: 2.48
Equity-to-Asset 0.37
FGEN's Equity-to-Asset is ranked lower than
99.99% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. FGEN: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
FGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.38 Max: 0.47
Current: 0.37
-0.3
0.47
Piotroski F-Score: 4
Altman Z-Score: 2.01
Beneish M-Score: -3.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -41.15
FGEN's Operating Margin % is ranked lower than
99.99% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. FGEN: -41.15 )
Ranked among companies with meaningful Operating Margin % only.
FGEN' s Operating Margin % Range Over the Past 10 Years
Min: -42.93  Med: -38.85 Max: -7.78
Current: -41.15
-42.93
-7.78
Net Margin % -45.93
FGEN's Net Margin % is ranked lower than
99.99% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. FGEN: -45.93 )
Ranked among companies with meaningful Net Margin % only.
FGEN' s Net Margin % Range Over the Past 10 Years
Min: -49.4  Med: -45.34 Max: -14.63
Current: -45.93
-49.4
-14.63
ROE % -42.81
FGEN's ROE % is ranked lower than
99.99% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. FGEN: -42.81 )
Ranked among companies with meaningful ROE % only.
FGEN' s ROE % Range Over the Past 10 Years
Min: -89.68  Med: -66.34 Max: -42.81
Current: -42.81
-89.68
-42.81
ROA % -16.48
FGEN's ROA % is ranked lower than
99.99% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. FGEN: -16.48 )
Ranked among companies with meaningful ROA % only.
FGEN' s ROA % Range Over the Past 10 Years
Min: -17.98  Med: -13.76 Max: -5.31
Current: -16.48
-17.98
-5.31
ROC (Joel Greenblatt) % -53.59
FGEN's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. FGEN: -53.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -57.05  Med: -27.62 Max: -3.35
Current: -53.59
-57.05
-3.35
GuruFocus has detected 3 Warning Signs with FibroGen Inc $FGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FGEN Guru Trades in Q1 2016

Paul Tudor Jones 19,593 sh (New)
Joel Greenblatt Sold Out
» More
Q2 2016

FGEN Guru Trades in Q2 2016

Paul Tudor Jones 10,993 sh (-43.89%)
» More
Q3 2016

FGEN Guru Trades in Q3 2016

Jim Simons 223,300 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2016

FGEN Guru Trades in Q4 2016

Joel Greenblatt 21,899 sh (New)
Paul Tudor Jones 17,575 sh (New)
Jim Simons 332,600 sh (+48.95%)
» More
» Details

Insider Trades

Latest Guru Trades with FGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:MPSYY, NAS:HALO, NAS:LXRX, NAS:FPRX, OTCPK:BVNRY, NAS:INVA, NAS:SRPT, NYSE:EBS, NAS:ARRY, NYSE:CBM, NAS:ACOR, NAS:ALDR, OTCPK:PFSCF, NAS:ONCE, NAS:RGEN, NAS:CORT, NAS:AGIO, NAS:XLRN, NAS:NKTR, OTCPK:BPMUF » details
Traded in other countries:1FG.Germany, FGEN.Mexico,
FibroGen Inc is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.

FibroGen Inc was incorporated in 1993 in Delaware. It is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The Company's focus in the areas of fibrosis and hypoxia-inducible factor biology has generated multiple programs targeting various therapeutic areas. Its product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases ("HIF-PHs"), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). FG-3019 is the Company's monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer and liver fibrosis. The Company's business area includes Europe and Japan. Certain of the components of its product candidates are acquired from single-source suppliers and have been purchased without long-term supply agreements. The Comapny do not have an alternative supplier of certain components of their product candidates. The Company faces competition from multiple other pharmaceutical and biotechnology companies, many of which have greater financial, technical and human resources and experience in product development, manufacturing and marketing. Its trademarks include "FibroGen". The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing, among other things, of its product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.

Ratios

vs
industry
vs
history
PB Ratio 8.64
FGEN's PB Ratio is ranked lower than
99.99% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. FGEN: 8.64 )
Ranked among companies with meaningful PB Ratio only.
FGEN' s PB Ratio Range Over the Past 10 Years
Min: 4.36  Med: 7.3 Max: 10.81
Current: 8.64
4.36
10.81
PS Ratio 9.26
FGEN's PS Ratio is ranked lower than
99.99% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. FGEN: 9.26 )
Ranked among companies with meaningful PS Ratio only.
FGEN' s PS Ratio Range Over the Past 10 Years
Min: 5.38  Med: 7.69 Max: 11.24
Current: 9.26
5.38
11.24
EV-to-EBIT 0.96
FGEN's EV-to-EBIT is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. FGEN: 0.96 )
Ranked among companies with meaningful EV-to-EBIT only.
FGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.2  Med: -17.8 Max: 0.96
Current: 0.96
-24.2
0.96
EV-to-EBITDA 1.04
FGEN's EV-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. FGEN: 1.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
FGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.2  Med: -19.4 Max: 1.04
Current: 1.04
-26.2
1.04
Current Ratio 4.11
FGEN's Current Ratio is ranked lower than
99.99% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. FGEN: 4.11 )
Ranked among companies with meaningful Current Ratio only.
FGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.88  Med: 3.8 Max: 4.51
Current: 4.11
2.88
4.51
Quick Ratio 4.11
FGEN's Quick Ratio is ranked lower than
99.99% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. FGEN: 4.11 )
Ranked among companies with meaningful Quick Ratio only.
FGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.88  Med: 3.8 Max: 4.51
Current: 4.11
2.88
4.51
Days Sales Outstanding 16.31
FGEN's Days Sales Outstanding is ranked lower than
99.99% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. FGEN: 16.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
FGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.31  Med: 38.36 Max: 48.63
Current: 16.31
16.31
48.63

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 8.62
FGEN's Price-to-Tangible-Book is ranked lower than
99.99% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. FGEN: 8.62 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FGEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.33  Med: 7.31 Max: 10.64
Current: 8.62
5.33
10.64
Price-to-Median-PS-Value 1.20
FGEN's Price-to-Median-PS-Value is ranked lower than
99.99% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. FGEN: 1.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.86  Med: 1 Max: 1.44
Current: 1.2
0.86
1.44
Earnings Yield (Greenblatt) % 103.68
FGEN's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. FGEN: 103.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 107.5
Current: 103.68
0
107.5

More Statistics

Revenue (TTM) (Mil) $172.1
EPS (TTM) $ -1.33
Short Percentage of Float5.27%
52-Week Range $14.50 - 25.70
Shares Outstanding (Mil)63.16

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 180 151 271 421
EPS ($) -0.87 -1.85 -0.89 0.34
EPS without NRI ($) -0.87 -1.85 -0.89 0.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for FGEN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017 Feb 22 2017
FIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Feb 16 2017
FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing... Feb 03 2017
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017 Jan 31 2017
Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen Jan 30 2017
Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6% Jan 30 2017
FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 30 2017
FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China Jan 30 2017
FibroGen (FGEN) Shares March Higher, Can It Continue? Jan 23 2017
Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers... Jan 20 2017
Here Are Two Market Moving Biotech Catalysts To Watch This Week Jan 17 2017
6 Major FDA Decisions and Biopharma Catalysts Coming in January and February Jan 06 2017
Will 2017 Be a Make or Break Year for FibroGen? Dec 30 2016
FibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : December 23, 2016 Dec 23 2016
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : December 22, 2016 Dec 22 2016
Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights Dec 20 2016
ETFs with exposure to FibroGen, Inc. : December 16, 2016 Dec 16 2016
Is FibroGen Inc (FGEN) a Good Stock to Buy? Dec 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)